Cocrystal Pharma (NASDAQ:COCP) Director Phillip Md Et Al Frost Purchases 50,000 Shares

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost bought 50,000 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were purchased at an average price of $0.95 per share, with a total value of $47,500.00. Following the completion of the acquisition, the director directly owned 1,888,551 shares in the company, valued at $1,794,123.45. This trade represents a 2.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, December 31st, Phillip Md Et Al Frost purchased 50,000 shares of Cocrystal Pharma stock. The shares were acquired at an average cost of $0.95 per share, for a total transaction of $47,500.00.
• On Tuesday, December 30th, Phillip Md Et Al Frost acquired 20,000 shares of Cocrystal Pharma stock. The stock was acquired at an average price of $0.97 per share, with a total value of $19,400.00.
• On Friday, December 26th, Phillip Md Et Al Frost bought 40,000 shares of Cocrystal Pharma stock. The shares were acquired at an average cost of $0.97 per share, for a total transaction of $38,800.00.
• On Wednesday, December 24th, Phillip Md Et Al Frost bought 25,000 shares of Cocrystal Pharma stock. The shares were acquired at an average price of $0.97 per share, for a total transaction of $24,250.00.
• On Wednesday, November 26th, Phillip Md Et Al Frost acquired 4,000 shares of Cocrystal Pharma stock. The stock was bought at an average price of $0.99 per share, for a total transaction of $3,960.00.
• On Tuesday, November 25th, Phillip Md Et Al Frost purchased 20,000 shares of Cocrystal Pharma stock. The stock was bought at an average cost of $0.94 per share, for a total transaction of $18,800.00.

Cocrystal Pharma Stock Performance

COCP stock opened at $0.95 on Tuesday. Cocrystal Pharma, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $2.67. The company’s 50 day moving average price is $1.02 and its 200 day moving average price is $1.21. The firm has a market capitalization of $13.09 million, a price-to-earnings ratio of -1.01 and a beta of 1.20.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. Equities analysts forecast that Cocrystal Pharma, Inc. will post -1.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.